Polar Healthcare (USD Class) (USD Class)

Reference Data

ISIN IE00B28YJN35
Valor Number 3619126
Bloomberg Global ID BBG000C22XY9
Fund Name Polar Healthcare (USD Class) (USD Class)
Fund Provider POLAR CAPITAL FUNDS PLC London, United Kingdom
Phone: +44 20 7227 2700
Web: www.polarcapital.co.uk
Fund Provider POLAR CAPITAL FUNDS PLC
Representative in Switzerland
Distributor(s) AIG Privat Bank AG
Zürich
Phone: +41 44 227 55 55
Asset Class Other Funds
EFC Category
Distribution Policy Other
Home Country Ireland
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies. The Fund will at all times invest at least two thirds of its total assets (excluding cash) in healthcare-related companies worldwide. The Fund will invest at least 51% of its gross assets on a continuous basis directly in Equity Participations. Subject to the investment restrictions described in Appendix II of the Prospectus, investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which may be listed on a Regulated Market or unlisted, and issued by companies, and Global, American and European depository receipts. The Fund may not invest more than 10% of its Net Asset Value in unlisted securities.
Peculiarities

Fund Prices

Current Price * 60.54 USD 08.01.2026
Previous Price * 60.34 USD 07.01.2026
52 Week High * 61.56 USD 26.11.2025
52 Week Low * 40.78 USD 09.04.2025
NAV * 60.54 USD 08.01.2026
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 2,163,393,949
Unit/Share Assets *** 20,790,795
Trading Information SIX

Performance

YTD Performance +2.61% 31.12.2025
08.01.2026
YTD Performance (in CHF) +3.35% 31.12.2025
08.01.2026
1 month +0.78% 08.12.2025
08.01.2026
3 months +6.36% 08.10.2025
08.01.2026
6 months +26.84% 08.07.2025
08.01.2026
1 year +23.32% 08.01.2025
08.01.2026
2 years +28.18% 08.01.2024
08.01.2026
3 years +43.53% 09.01.2023
08.01.2026
5 years +36.41% 08.01.2021
08.01.2026

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 9.59%
UCB SA 7.27%
argenx SE 5.95%
Zealand Pharma AS 4.66%
Teva Pharmaceutical Industries Ltd ADR 4.65%
Fresenius SE & Co KGaA 3.88%
Chugai Pharmaceutical Co Ltd 3.50%
Boston Scientific Corp 3.42%
Cytokinetics Inc 3.25%
Ascendis Pharma AS ADR 3.04%
Last data update 30.11.2025

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.61%
SRRI ***
SRRI date *** 31.12.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)